Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($10.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.77) by ($8.42), FiscalAI reports.
Jasper Therapeutics Stock Performance
Shares of NASDAQ JSPR opened at $13.68 on Monday. The firm has a market cap of $15.16 million, a P/E ratio of -0.29 and a beta of 3.30. Jasper Therapeutics has a 1-year low of $9.45 and a 1-year high of $72.60. The business’s 50 day moving average is $16.79 and its 200-day moving average is $24.15.
Analyst Upgrades and Downgrades
Several equities analysts have commented on JSPR shares. William Blair began coverage on shares of Jasper Therapeutics in a report on Wednesday, October 14th. They issued an “outperform” rating on the stock. Wall Street Zen cut shares of Jasper Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright restated a “buy” rating on shares of Jasper Therapeutics in a research note on Tuesday, August 18th. Finally, Piper Sandler assumed coverage on shares of Jasper Therapeutics in a report on Wednesday, August 12th. They set an “overweight” rating and a $60.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $220.00.
About Jasper Therapeutics
Jasper Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for conditions involving blood-forming stem cells and mast cells. Its research focuses on c-Kit, also known as CD117, a protein found on these cells. The company’s lead investigational drug, briquilimab (formerly JSP191), is a monoclonal antibody that targets c-Kit. Jasper has studied briquilimab as a conditioning treatment for stem cell transplantation and gene therapy, and is evaluating it for mast cell-mediated diseases, including chronic spontaneous urticaria.
Read More
- Five stocks we like better than Jasper Therapeutics
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
